‌

US Patent 8802858 Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases

Patent 8802858 was granted and assigned to Basilea Pharmaceutica on August, 2014 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent

Patent attributes

Current Assignee

Basilea Pharmaceutica

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

88028580

Patent Inventor Names

Felix Bachmann0

Jens Pohlmann0

Date of Patent

August 12, 2014

Patent Application Number

133844670

Date Filed

July 26, 2010

Patent Citations Received

‌

US Patent 11891382 Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof

Patent Primary Examiner

‌

Heidi Reese

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8802858 Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API